The RAND study revealed confusion among veterans about the VA's policies regarding psychedelics.
The increased public discourse and research into psychedelics have reached a point where their use, even among specific populations like veterans, is being formally studied and reported.
This study highlights an emerging shift in perceptions and potential policy changes regarding psychedelic therapies, which could impact veteran healthcare, mental health strategies, and the pharmaceutical industry.
The reported widespread use among veterans and their confusion over VA policies indicates a growing demand for and acceptance of psychedelics that existing healthcare frameworks are struggling to address.
- · Psychedelic therapy researchers
- · Mental health advocacy groups
- · Veterans seeking alternative treatments
- · Traditional psychotherapy providers
- · Pharmaceutical companies focused on conventional mental health drugs with limite
The study will likely prompt the VA to clarify or re-evaluate its stance on psychedelic treatments for veterans.
Increased acceptance within the veteran community could pave the way for broader medical legalization and integration of psychedelics into national healthcare systems.
This could accelerate the bio-pharmaceutical industry's investment into developing and commercializing psychedelic-assisted therapies, disrupting existing mental health paradigms.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at Air Force Times